Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

Seattle Cancer Care Alliance Network Investigators

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Chemotherapy remains the mainstay of metastatic triple negative breast cancer treatment; however, angiogenesis and epidermal growth factor receptor are potential targets. The present phase II clinical trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, demonstrated progression-free survival similar to that with other regimens. Most patients experienced a partial response and received maintenance therapy, resulting in a significant break from cytotoxic chemotherapy.

Original languageEnglish (US)
JournalClinical Breast Cancer
DOIs
StatePublished - Jan 1 2019

Fingerprint

Breast
Maintenance
Triple Negative Breast Neoplasms
Drug Therapy
Phase II Clinical Trials
Epidermal Growth Factor Receptor
Disease-Free Survival
Therapeutics
Bevacizumab
130-nm albumin-bound paclitaxel
Erlotinib Hydrochloride

Keywords

  • Circulating endothelial cells
  • Circulating tumor cells
  • Erlotinib
  • Metastatic
  • Nab-paclitaxel bevacizumab
  • Triple negative breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{b0e466221ba844269081b908119f1e8f,
title = "Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib",
abstract = "Chemotherapy remains the mainstay of metastatic triple negative breast cancer treatment; however, angiogenesis and epidermal growth factor receptor are potential targets. The present phase II clinical trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, demonstrated progression-free survival similar to that with other regimens. Most patients experienced a partial response and received maintenance therapy, resulting in a significant break from cytotoxic chemotherapy.",
keywords = "Circulating endothelial cells, Circulating tumor cells, Erlotinib, Metastatic, Nab-paclitaxel bevacizumab, Triple negative breast cancer",
author = "{Seattle Cancer Care Alliance Network Investigators} and Lynn Symonds and Hannah Linden and Vijayakrishna Gadi and Larissa Korde and Eve Rodler and Julie Gralow and Mary Redman and Kelsey Baker and Wu, {Quan (Vicky)} and Isaac Jenkins and Brenda Kurland and Mitchell Garrison and Julie Smith and Jeanne Anderson and {Van Haelst}, Carol and Jennifer Specht",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.clbc.2018.12.008",
language = "English (US)",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",

}

TY - JOUR

T1 - Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

AU - Seattle Cancer Care Alliance Network Investigators

AU - Symonds, Lynn

AU - Linden, Hannah

AU - Gadi, Vijayakrishna

AU - Korde, Larissa

AU - Rodler, Eve

AU - Gralow, Julie

AU - Redman, Mary

AU - Baker, Kelsey

AU - Wu, Quan (Vicky)

AU - Jenkins, Isaac

AU - Kurland, Brenda

AU - Garrison, Mitchell

AU - Smith, Julie

AU - Anderson, Jeanne

AU - Van Haelst, Carol

AU - Specht, Jennifer

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Chemotherapy remains the mainstay of metastatic triple negative breast cancer treatment; however, angiogenesis and epidermal growth factor receptor are potential targets. The present phase II clinical trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, demonstrated progression-free survival similar to that with other regimens. Most patients experienced a partial response and received maintenance therapy, resulting in a significant break from cytotoxic chemotherapy.

AB - Chemotherapy remains the mainstay of metastatic triple negative breast cancer treatment; however, angiogenesis and epidermal growth factor receptor are potential targets. The present phase II clinical trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, demonstrated progression-free survival similar to that with other regimens. Most patients experienced a partial response and received maintenance therapy, resulting in a significant break from cytotoxic chemotherapy.

KW - Circulating endothelial cells

KW - Circulating tumor cells

KW - Erlotinib

KW - Metastatic

KW - Nab-paclitaxel bevacizumab

KW - Triple negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85060977590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060977590&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2018.12.008

DO - 10.1016/j.clbc.2018.12.008

M3 - Article

C2 - 30737173

AN - SCOPUS:85060977590

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

ER -